Ayala Pharmaceuticals announced that the U.S. Food and Drug Administration has granted Orphan Drug Designation to AL102, a Gamma Secretase Inhibitor, for the treatment of desmoid tumors. AL102 is an investigational small molecule GSI, currently being evaluated in the Phase 3 RINGSIDE study in DT. Orphan drug designation is granted by the FDA to drugs and biologics intended for treatment, prevention or diagnosis of a rare disease or condition that affects fewer than 200,000 people in the U.S. at the time of designation.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on ADXS:
- Ayala Pharmaceuticals treatment of desmoid tumors granted orphan designation
- Ayala Pharmaceuticals presents updated AL102 results at ESMO congress
- Ayala Pharmaceuticals Presents Updated AL102 Results from Phase 2 Clinical Trial in Desmoid Tumors at ESMO Congress 2023
- Ayala Pharmaceuticals closes merger with Biosight
- Ayala Pharmaceuticals Announces Closing of Merger with Biosight
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue